The University of Massachusetts (UMass) has begun dosing participants with Tiziana Life Sciences’ lead development candidate, intranasal foralumab, as part of an ongoing Phase II trial in patients with non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women’s Hospital (BWH), Yale Multiple Sclerosis Center, and Johns… Read More
New study results have demonstrated the anti-inflammatory potential of Tiziana Life Sciences’ anti-CD3 antibody foralumab in combination with semaglutide (Ozempic/Wegovy). The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO). Read More
Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. “With the FDA approval of the humanised anti-CD3 mAb TZIELD (teplizumab-mzwv injection) and then its subsequent announced acquisition of Provention Bio by Sanofi for… Read More
